From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer

1 month ago 23

Jonathan Ponciano, The Motley Fool

Mon, February 23, 2026 astatine 9:57 AM CST 3 min read

On February 17, 2026, Commodore Capital disclosed successful a U.S. Securities and Exchange Commission (SEC) filing that it sold each 2,338,287 shares of Agios Pharmaceuticals (NASDAQ:AGIO) successful the 4th quarter, an estimated $93.86 cardinal transaction.

According to a filing with the Securities and Exchange Commission dated February 17, 2026, Commodore Capital sold each 2,338,287 shares of Agios Pharmaceuticals successful the 4th quarter. The position’s quarter-end worth decreased by $93.86 cardinal arsenic a result.

Top holdings aft the filing:
- NASDAQ:RLAY: $143.82 cardinal (9.6% of AUM)
- NASDAQ:ALKS: $99.33 cardinal (6.6% of AUM)
- NASDAQ:TYRA: $88.73 cardinal (5.9% of AUM)
- NASDAQ:XENE: $80.68 cardinal (5.4% of AUM)
- NASDAQ:SYRE: $78.24 cardinal (5.2% of AUM)
As of February 17, 2026, shares of Agios Pharmaceuticals were priced astatine $27.82, down 17% implicit the past twelvemonth and good underperforming the S&P 500’s astir 13% summation successful the aforesaid period.

Metric

Value

Market Capitalization	$1.63 billion
Revenue (TTM)	$54.03 million
Net Income (TTM)	($412.78 million)
Price (as of marketplace adjacent 2/17/26)	$27.82

Agios Pharmaceuticals focuses connected the improvement and commercialization of medicines targeting cellular metabolism, including PYRUKYND (mitapivat) for hemolytic anemias.
The steadfast generates gross chiefly done income of proprietary therapies and ongoing objective improvement programs successful uncommon hematologic diseases.
It serves healthcare providers and patients with uncommon familial and acquired humor disorders, peculiarly those affected by hemolytic anemias.

Agios Pharmaceuticals, Inc. is simply a biopharmaceutical institution specializing successful therapies for uncommon hematologic diseases, leveraging expertise successful cellular metabolism. The company's strategy centers connected advancing innovative treatments from probe done commercialization, with a absorption connected precocious unmet aesculapian needs. With a pipeline anchored by PYRUKYND and ongoing objective programs, Agios aims to found a competitory presumption successful the uncommon illness abstraction by delivering novel, targeted therapies to patients and healthcare providers.

Capital successful biotech rotates toward momentum and distant from frustration. That discourse matters here. Agios banal tumbled 50% successful 1 time aft the Phase 3 RISE UP proceedings of mitapivat missed connected reducing sickle compartment symptom crises, reversing large gains from earlier successful the year. Only making the banal harder to digest, profitability remains distant. The institution posted a $108 cardinal nett nonaccomplishment successful the 4th fourth (compared to a $96.5 cardinal nonaccomplishment 1 twelvemonth earlier). Shares astatine $28 are down astir 17% implicit the past 12 months, sharply trailing the broader market.

Within this portfolio, superior is concentrated successful clinical-stage immunology names specified arsenic Relay, Alkermes, Tyra, Xenon, and Spyre, each betwixt astir 5% and 10% of assets. Agios, a commercial-stage uncommon illness player, sat somewhat extracurricular that halfway theme.

For semipermanent investors, the connection is not that Agios lacks assets. It is that execution present matters much than optionality.

Read Entire Article